Millennium Pharma. ++ steigt + steigt + steigt ++ - 500 Beiträge pro Seite

[uwsei]

Millennium steigt außerbörslich stark an, weiß jemand
was da los ist? Am 23.01.01 ist doch HV!
Danke vorab.

[JavierOxtoa]

na übertreib mal nicht

von 45,18 auf 47 sind 4%!!

Wahrscheinlich bedingt durch das Amgen-Urteil.

[igor1]

Dienstag, 23. Januar 2001 Quartalszahlen
Unternehmen
Millennium Pharmaceuticals, Inc.


Bekanntgabe nach Börsenschluss (USA).

[igor1]

Percent Change After Hours +5.12%
Shares Matched After Hours 3,525
Shares Booked After Hours 48,836
Orders Booked After Hours 122
Last Trade Time 19:41:39.72
Last Order Time 19:31:51.57
Open Orders 73
LAST 20 ISLAND TRADES FOR MLNM
1. 19:41:39.72: 100 at 47.5000
2. 19:37:05.19: 200 at 47.0000
3. 19:22:17.17: 100 at 47.2500
4. 19:18:24.15: 100 at 47.5000
5. 18:16:41.23: 14 at 47.5000
6. 18:10:21.66: 100 at 47.0000
7. 18:10:21.66: 170 at 47.0000
8. 17:05:03.92: 20 at 46.5000
9. 17:03:45.60: 200 at 46.5000
10. 17:03:44.32: 200 at 46.5000
11. 16:55:10.67: 20 at 45.8750
12. 16:55:10.67: 80 at 45.7500
13. 16:55:08.58: 200 at 45.7500
14. 16:52:13.09: 20 at 45.7500
15. 16:17:56.51: 100 at 45.0000
16. 16:12:58.56: 300 at 45.1875
17. 16:07:17.28: 13 at 45.5000
18. 16:02:17.91: 87 at 45.1240
19. 16:01:44.21: 1 at 45.0000
20. 16:00:31.76: 500 at 44.8750


--------------------------------------------------------------------------------

Nasdaq closing quote data delayed at least 15 minutes.

All volume numbers count the number of shares that changed beneficial ownership.
All times are US Eastern time zone.
NASDAQ test stocks are excluded from all displays and calculations.
A `#` indicator on a last trade price indicates the price has been rounded away.

--------------------------------------------------------------------------------

[igor1]

bei L & S


WKN

900625
Name
MILLENN PHARM
BID
50.08 EUR
ASK
51.68 EUR
Zeit
20.01.01 - 15:42:26 Uhr

[SmartFool]

Hi liebe Trader,

habe bei MUSTER-AKTIEN.de einen sehr interessanten Bericht über MLNM gefunden.
Außerdem haben die haben den Wert jetzt sogar in ihr spekulatives Trading-depot aufgenommen.

Euer Smart

[abzocker02]

Die Aktie von Millenium Pharm. ist sicher ein Kauf ! Ich würde allerdings erstmal auf Morgen abwarten da meldet MLNM nächmlich die Zahlen für das 4 Q. und die werden sicher gut ausfallen.

Ich bin voll in MLNM isvestieret und hoffe daher auf gute Zahlen gleich wie ich im Glasfaersector investiert bin habe ich auf gute Zahlen gehofft und die sind auch gekommen aber jetzt scheint es schon wieder gewinnmitnahmen zu geben das darf doch nicht war sein !

MLNM sicht auf ende der Jahres : 90$

MLNM in 10 Jahren: 230$

Gruß
abzocker

[igor1]

@ abzocker
shorties verkaufen
Grosse kaufen
sehe mein tread . MILLENIUM (MLNM)

[abcman]

Hallo Leute,
millennium hat doch gestern abend Quartalszahlen veröffentlicht oder habe ich mich etwa verhört.
Geschätzt waren 0,05 Cent Verlust/Aktie, angegeben
wurden jedoch 0,07 Cent Verlust.
Hoffe aber das ich mich verhört habe!
Hat jemand genauere Zahlen oder besitzt niemand mehr diese
Aktie?
Vor der Veröffentlichung stieg Millennium in den USA ja kräftig an, aber nach diesen Zahlen wird es wohl wieder ein wenig Abwärts gehen. Ich hoffe aber das die Prognosen für das Jahr 2001 positiv ausgefallen sind.
Danke
abcman

[inkjet]

NEW YORK, Jan 23 (Reuters) - Biotech firm Millennium Pharmaceuticals Inc. (NasdaqNM:MLNM - news) on Tuesday reported a lower-than-expected loss in the fourth quarter, compared with a slight profit in the same period last year.

The Cambridge, Mass.-based company, which uses an array of sophisticated equipment to discover genes and their functions, reported a quarterly net loss, before special items, of $4.4 million, or 2 cents per share, compared to a profit of $1.7 million, or 1 cent per share, in the year-ago period.

Analysts polled by research firm First Call/Thomson Financial expected the company to lose 5 cents per share.

Revenues, all from alliances with other firms, rose to $70 million from $55 million in the year-ago quarter, amid growing numbers of alliances with other biotech firms and interest from investments. But its research and development costs rose to $78 million from $47 million in the 1999 quarter.

Millennium`s revenue for 2000 was $213 million, excluding a one-time charge of $108 million taken in the fourth quarter under a change of accounting procedures. It had revenues in 1999 of $184 million.

``The increase in revenue is due to the addition of new alliances formed in 2000 and the ongoing success of existing relationships,`` Millennium said in a release.

But growing research costs contributed to an operating loss in 2000 of $75 million, or $0.39 per share, compared to net operating income of $2.4 million, or $0.02 per share, in 1999.

Looking ahead, the prominent gene-hunting firm said it expects 2001 revenues of between $220 million and $240 million, a bit higher than 2000, and an operating loss for 2001 in a range of $100-$125 million.

Millennium attributed part of the expected loss to growing costs of research and development, which it said would total $375 million to $400 million for 2001. That compares with $269 million spent on R&D in 2000.

Robertson Stephens biotech analyst Edward Tenthoff said Millennium has filed about 1,400 patent applications, many of them for genes, and was wise to spend more of its $1.5 billion cash hoard on drug-discovery research.

In the past several years, Millennium has forged alliances with many of the world`s largest pharmaceuticals firms -- trying to identify which genes, enzymes and proteins are linked to specific diseases.

``Just two years ago, Millennium was basically acting as a gene-discovery engine for other companies. But now it is adroitly positioning itself to become a pharmaceuticals firm in its own right,`` said Tenthoff, who previously had expected the firm to devote only about $300 million for R&D in 2001.

Tenthoff said Millennium has long-term research commitments of about $1.8 billion from other drug companies, somewhat below the $2 billion in pledges it had hoped to amass by the end of 2000.

In older deals, Millennium is entitled only to royalties on sales of future drugs developed by its collaborators. But increasingly, it is demanding an equal share of profits.

Germany`s Bayer AG and Millennium said on Jan. 10 that joint cancer research had yielded early success with clinical trials of a drug candidate set to start this year.

Just a day earlier, Millennium and American Home Products Corp. (NYSE:AHP - news) said they had come up with a promising experimental antibiotic which is still being tested in animals.

Last month, Millennium and collaborator ILEX Oncology Inc.

(NasdaqNM:ILXO - news) won support from an advisory panel of the U.S. Food and Drug Administration for their experimental leukemia drug, Campath. Analysts have said it could garner annual sales of $100 million or more if approved by the FDA, which usually follows the recommendations of its advisory panels.

Millennium shares on Tuesday closed up $4-9/16 or almost 10 percent to $52-9/16 on the Nasdaq before earnings results were released late in the afternoon. They have traded in the past year between $23-3/4 and $89-13/16.

[Zoroaster]

Falls noch Unklarheiten bestehen:
Mlnm ist die Aktie der nächsten Jahre im Biotech-Sektor:
Wenn heute die 52 Dollar gehalten werden, heißt das, daß die Großinvestoren einsteigen, Fonds und ähnliches, dann geht das Teil auf die 100 Dollar, also mit Sicherheit die alten Höchststände von Juli-August 00 überbietend:

UPDATE 2)-Millennium Pharma Q4 loss lower than expected
TUESDAY, JANUARY 23, 2001 7:41 PM
- Reuters

(adds analyst comments, paragraphs 10, 12-14)

NEW YORK, Jan 23 (Reuters) - Biotech firm Millennium Pharmaceuticals Inc. (NASDAQ NM:MLNM) on Tuesday reported a lower-than-expected loss in the fourth quarter, compared with a slight profit in the same period last year.

The Cambridge, Mass.-based company, which uses an array of sophisticated equipment to discover genes and their functions, reported a quarterly net loss, before special items, of $4.4 million, or 2 cents per share, compared to a profit of $1.7 million, or 1 cent per share, in the year-ago period.

Analysts polled by research firm First Call/Thomson Financial expected the company to lose 5 cents per share.

Revenues, all from alliances with other firms, rose to $70 million from $55 million in the year-ago quarter, amid growing numbers of alliances with other biotech firms and interest from investments. But its research and development costs rose to $78 million from $47 million in the 1999 quarter.

Millennium`s revenue for 2000 was $213 million, excluding a one-time charge of $108 million taken in the fourth quarter under a change of accounting procedures. It had revenues in 1999 of $184 million.

"The increase in revenue is due to the addition of new alliances formed in 2000 and the ongoing success of existing relationships," Millennium said in a release.

But growing research costs contributed to an operating loss in 2000 of $75 million, or $0.39 per share, compared to net operating income of $2.4 million, or $0.02 per share, in 1999.

Looking ahead, the prominent gene-hunting firm said it expects 2001 revenues of between $220 million and $240 million, a bit higher than 2000, and an operating loss for 2001 in a range of $100-$125 million.

Millennium attributed part of the expected loss to growing costs of research and development, which it said would total $375 million to $400 million for 2001. That compares with $269 million spent on R&D in 2000.

Robertson Stephens biotech analyst Edward Tenthoff said Millennium has filed about 1,400 patent applications, many of them for genes, and was wise to spend more of its $1.5 billion cash hoard on drug-discovery research.

In the past several years, Millennium has forged alliances with many of the world`s largest pharmaceuticals firms -- trying to identify which genes, enzymes and proteins are linked to specific diseases.

"Just two years ago, Millennium was basically acting as a gene-discovery engine for other companies. But now it is adroitly positioning itself to become a pharmaceuticals firm in its own right," said Tenthoff, who previously had expected the firm to devote only about $300 million for R&D in 2001.

Tenthoff said Millennium has long-term research commitments of about $1.8 billion from other drug companies, somewhat below the $2 billion in pledges it had hoped to amass by the end of 2000.

In older deals, Millennium is entitled only to royalties on sales of future drugs developed by its collaborators. But increasingly, it is demanding an equal share of profits.

Germany`s Bayer AG ( and Millennium said on Jan. 10 that joint cancer research had yielded early success with clinical trials of a drug candidate set to start this year.

Just a day earlier, Millennium and American Home Products Corp. (NYSE:AHP) said they had come up with a promising experimental antibiotic which is still being tested in animals.

Last month, Millennium and collaborator ILEX Oncology Inc.
(NASDAQ NM:ILXO) won support from an advisory panel of the U.S. Food
and Drug Administration for their experimental leukemia drug,
Campath. Analysts have said it could garner annual sales of
$100 million or more if approved by the FDA, which usually
follows the recommendations of its advisory panels.

Millennium shares on Tuesday closed up $4-9/16 or almost 10 percent to $52-9/16 on the Nasdaq before earnings results were released late in the afternoon. They have traded in the past year between $23-3/4 and $89-13/16.

Rtr 19:41 01-23-01

Selector Code: reuco

Copyright 2001, Reuters News Service

[dosto]

kann es sein dass der tread von der überschrift her
flasch ist?

[Kostolany4]

@dosto
Warum mußtest Du diesen blödsinnigen Thread, der einen Monat lang schon
in der Versenkung verschwunden war, eigentlich ausgraben ?

==> Bitte lasse diese dummen Scherze doch einfach sein.

Wir übrigen Boardbenutzer, die an aktueller Information interessiert sind,
wären Dir zu Dank verpflichtet.

Kostolany4
kopfschüttelnd